Biotech: Page 3

  • Image attribution tooltip
    Courtesy of Galapagos

    Galapagos, with latest deals, charts an unexpected journey to cell therapy

    The Belgian drugmaker will spend more than $100 million to acquire two companies, CellPoint and AboundBio, in a move meant to “disrupt” CAR-T treatment.

    By June 22, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    A biotech startup launches with $38M to develop a cystic fibrosis gene therapy

    Carbon Biosciences believes its technology, which is based on parvoviruses, could allow for larger gene delivery and repeat dosing.

    By June 21, 2022
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.

    Cell therapy

    Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.

    By BioPharma Dive staff
  • Image attribution tooltip
    E+ via Getty Images

    Boehringer extends cancer dealmaking with right to buy biotech partner

    The German pharma company has secured an option to acquire Trutino Biosciences, two years after inking a research collaboration with the San Diego drug developer. 

    By June 16, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images

    With biotech in retreat, Third Rock raises $1B for life sciences investing

    The fund, Third Rock’s sixth, comes amid a significant downturn in biotech stocks, which has raised questions about the viability of young drug startups.

    By June 15, 2022
  • A 3D rendering of the CRISPR-cas9 gene editing system.
    Image attribution tooltip
    Meletios Verras via Getty Images
    CRISPR gene editing

    Vertex, CRISPR strengthen case for pioneering gene-editing treatment

    Positive data from 75 patients with either sickle cell disease or beta thalassemia keep the companies’ therapy on track to become the first CRISPR-based treatment submitted to drug regulators, possibly by the end of the year.

    By June 11, 2022
  • Human respiratory syncytial virus virions are shedding from the surface of human lung cells.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.

    GSK claims first positive Phase 3 result for an RSV vaccine

    The British drugmaker now plans to seek approval of what could be the first preventive shot for the common lung infection. However, Pfizer, Johnson & Johnson and Moderna are close behind. 

    By June 10, 2022
  • Image attribution tooltip
    Kena Betancur via Getty Images

    Forbion raises $500M to back growing biotechs amid industry slump

    The European venture firm’s latest fund will open up a new source of investment at a time companies are struggling to go public or hold their value.

    By June 10, 2022
  • Alnylam follows rivals with new study results for kidney disease drug

    An experimental medicine the company is developing with Regeneron has shown early promise treating IgA nephropathy, a disease that’s become a competitive target among drugmakers.

    By June 9, 2022
  • Novavax COVID-19 candidate vaccine NVX-CoV2373 administered to first patients in Phase I Clinical Trial
    Image attribution tooltip
    Courtesy of Novavax, Australian Broadcasting Corporation

    FDA advisers back Novavax's latecomer COVID-19 vaccine

    Outside experts debated the shot's safety profile and its efficacy versus the omicron variant but ultimately supported the vaccine, which is made using more traditional technology than Pfizer's and Moderna's.

    By Updated June 7, 2022
  • Biotech Athersys to lay off 70% of staff in cost-cutting effort

    The stem cell therapy company said the restructuring is meant as a first step toward making it "more attractive" to potential financial and strategic partners.

    By June 6, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA extends review of Amylyx ALS drug, delaying approval decision

    The agency said it wanted more time to assess additional clinical trial data submitted by Amylyx, and set a new decision date of Sept. 29 for the closely watched treatment. 

    By June 3, 2022
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers bets $4B on Turning Point and its targeted cancer drugs

    While priced at a significant premium, the deal values Turning Point well below its peak valuation last year, a potential sign biotechs might be adjusting their expectations amid the sector's downturn.

    By Updated June 3, 2022
  • Image attribution tooltip
    Courtesy of Roche

    Roche gambles $125M on a sliding biotech's cancer drug

    Months after early results from Repare Therapeutics' drug disappointed analysts, the Swiss pharma has acquired rights, betting it may prove useful in combinations with other treatments.

    By Kristin Jensen • June 2, 2022
  • A photograph of Tessera Therapeutics CEO and Flagship Pioneering Partner Michael Severino
    Image attribution tooltip
    Permission granted by Tessera Therapeutics

    Former AbbVie executive Severino joins Flagship-backed startup as CEO

    Severino left the pharma company in April after eight years as its chief scientist and then president. He'll lead Tessera Therapeutics, a well-funded genetic medicine startup.

    By June 2, 2022
  • A photograph of Upstream Bio CEO Samantha Truex
    Image attribution tooltip
    Permission granted by Upstream Bio

    Upstream Bio, a richly funded startup, reveals its lead drug and research plans

    Backed by $200 million in funding and led by biotech veteran Samantha Truex, Upstream is developing a clinical-stage inflammatory disease drug acquired from Astellas last year.

    By June 2, 2022
  • Biogen
    Image attribution tooltip
    Permission granted by Biogen

    Sage, Biogen drug meets goal in postpartum depression study

    The results will help support an application for FDA approval, which the companies plan to submit early next year. They are already seeking an OK for their treatment in major depressive disorder.

    By June 1, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    BioMarin delays planned FDA filing for hemophilia gene therapy

    The California biotech now expects to resubmit its approval application to the FDA by the end of September, the latest regulatory setback for its closely watched treatment. 

    By May 31, 2022
  • Image attribution tooltip
    National Cancer Institute, NIH

    Mirati matches Amgen with updated data for KRAS-blocking cancer drug

    Fresh study results showed similar rates of response and progression-free survival with Mirati's experimental adragasib as with Amgen's approved Lumakras. The new data might raise safety questions, however. 

    By Updated May 27, 2022
  • Image attribution tooltip
    Editas Medicines

    Former Editas CEO Bosley joins UK venture capital firm

    Bosley, who once led the CRISPR gene editing biotech, will become a venture partner at Advent Life Sciences, which backs a range of early-stage drug companies.

    By May 26, 2022
  • A cash-strapped biotech winds down operations

    With the market for biotech stocks constrained, Genocea Biosciences plans to delist from Nasdaq and lay off the its remaining employees.

    By Kristin Jensen • May 25, 2022
  • Image attribution tooltip

    Responding to outbreak, Moderna starts early work on monkeypox vaccine

    One day after the U.S. began releasing supplies of an approved Bavarian Nordic shot, Moderna said it's beginning development of its own vaccine against the virus.

    By May 24, 2022
  • Image attribution tooltip
    Getty Images

    Springworks shares fall despite drug trial's success

    The biotech plans to seek FDA approval for its soft-tissue tumor treatment after positive study results. But investors still sent the stock down by nearly 10%.

    By May 24, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Concert drug helps regrow hair in study, boosting shares

    There are no treatments specifically approved for alopecia areata. Concert follows Pfizer and Eli Lilly in reporting positive late-stage results for drugs the companies are developing for the autoimmune disorder.

    By May 23, 2022
  • Image attribution tooltip
    Westend61 via Getty Images
    Sponsored by GoodRx

    Common barriers to patient engagement: What's your strategy?

    As with treatment, and even adherence, there is no 'one size fits all' when it comes to patient engagement.

    May 23, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    PTC's first gene therapy gains European regulator's backing

    The brain-infused treatment for a rare neurological disease would be one of only three gene therapies commercially available in the EU. PTC plans to ask for FDA approval later this year.

    By May 20, 2022